Patient characteristics
| No. | 177 |
| Median age (y) (range) | 60 (21-82) |
| Female/male | 66/111 |
| Rai stage | |
| 0 | 44 |
| I | 78 |
| II | 24 |
| III | 8 |
| IV | 23 |
| No. patients previously treated (%) | 75 (42) |
| β2-microglobulin (n = 153) | 2.7 mg/L |
| Median (range) | (0.9-16.8 mg/L) |
| No. previous treatments | |
| 0 | 102 |
| 1 | 43 |
| 2 | 14 |
| 3 | 10 |
| 4 or more | 8 |
| Median serum IL-10 (range) (pg/mL) | 5.04 (0-74) |
| Median serum IL-6 (range) (pg/mL) | 1.45 (0-110) |
| Median follow-up of survivors (mo) | 30 (1-40) |
| No. patients dead (%) | 42 (24) |
| Median survival (mo) | Not reached |
| No. | 177 |
| Median age (y) (range) | 60 (21-82) |
| Female/male | 66/111 |
| Rai stage | |
| 0 | 44 |
| I | 78 |
| II | 24 |
| III | 8 |
| IV | 23 |
| No. patients previously treated (%) | 75 (42) |
| β2-microglobulin (n = 153) | 2.7 mg/L |
| Median (range) | (0.9-16.8 mg/L) |
| No. previous treatments | |
| 0 | 102 |
| 1 | 43 |
| 2 | 14 |
| 3 | 10 |
| 4 or more | 8 |
| Median serum IL-10 (range) (pg/mL) | 5.04 (0-74) |
| Median serum IL-6 (range) (pg/mL) | 1.45 (0-110) |
| Median follow-up of survivors (mo) | 30 (1-40) |
| No. patients dead (%) | 42 (24) |
| Median survival (mo) | Not reached |
IL-10 indicates interleukin 10; IL-6, interleukin 6.